Hexen
Hexen is also known as N – Ethylhexedrone and it belongs to the cathinone family. The substance is relatively new, only entering the recreational drug market within the last decade. It was created as part of the group of compounds called substituted cathinones. This group includes several stimulant substances.
Basic Information
- Chemical Name: N-Ethylhexedrone
- Other Known names: Hexen (NEH), Ethyl Hexadrone
- CAS number: 18410-63-2
- Formula Molecular: C14H21NO
- Chemical structure: CH3 (CH2)5CON (CH2)2
- Drug Class: Stimulants, Substituted Cathinones
Physical Characteristics
Hexen is typically a powdery white substance. The color of hexen can be affected by its purity and the way it was manufactured.
Use and effects
Hexen is a stimulant. This means that it increases the levels of physiological activity or nervous activity within the body. Hexen is known to produce effects like euphoria and increased sociability. It also increases mental and physical stimulation and improves focus. Hexen has been compared with drugs such as cocaine and methamphetamine. However, these effects vary from person to person.
Hexen dosages are not well-established due to the limited research on and understanding of Hexen. The substance is usually inhaled or taken orally. Dosages vary from 10 to 100mg, depending on the user and the method of administration. These figures should still be taken with caution as they can cause severe side effects such as increased heart rate and anxiety.
Important Notice
Hexen may be legal to purchase and sell for research in certain jurisdictions, but its use by health authorities is not regulated. It’s associated with serious health risks, and the potential for addiction and abuse. It should only be used under supervision by a professional.
To ensure that this substance is handled and disposed of in accordance with local and national laws, it must be used for scientific research. When working with Hexen, always use the appropriate safety equipment and follow all procedures.
Reviews
There are no reviews yet.